ESGCT Rome
Anemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to European Society of Gene & Cell Therapy 2024 in Rome, Italy
read morePeople & Career | News |
Anemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to European Society of Gene & Cell Therapy 2024 in Rome, Italy
read moreQuality assurance (QA) is crucial in the manufacturing of plasmid DNA (pDNA), a key component in gene therapy, vaccine development, genome editing, and synthetic biology.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Cell & Gene Meeting on the Mesa in Phoenix, Arizona
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to CPHI Milan 2024
read moreDiscover the pivotal role of plasmid DNA sequencing in advancing gene therapy. Learn how this groundbreaking technology is driving the development of novel treatments and shaping the future of biomedicine.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to ATE24 Lisbon, Portugal
read moreDownstream process is fine tuned to recover the soluble fraction of plasmidic DNA, whereas the genomic DNA, proteins polysaccharides and total RNA from E. coli cells are precipitated and removed by depth filtration.
read moreA plasmid is a circular double-stranded DNA molecule that exists separately from the chromosomal DNA within a cell.
read moreThe utilization of plasmid DNA in the production of viral vectors for gene therapy represents a critical advancement in medical biotechnology.
read moreLentiviruses and adeno-associated viruses (AAV) require specific plasmids for their production, which ensure efficient vector generation and safe delivery of the gene of interest (GOI).
read moreMany people first became familiar with the term “mRNA” when COVID-19 vaccines were rolled out. In the simplest terms, mRNA, which stands for messenger ribonucleic acid, is a genetic material that instructs the cells to make specific proteins.
read moreAnemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961